XERSXeris Biopharma Holdings, Inc.
Price
+36%1YEnd-of-day closes, not the intraday tick.
Survival is the story here: start there
Quality strong, hard red flags, demanding price, growing in the filings, the market undecided.
We are a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. We offer Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis ("PPP"). We are advancing our Phase 3-ready pipeline product, XP-8121, once-weekly subcutaneous ("SC") levothyroxine, which leverages our proprietary technology XeriSol.
In the company’s own words · 10-K filed Mar 2, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Xeris Biopharma Holdings, Inc. (XERS) reported revenue of $92M in Q2 2026 (quarter ended Jun 30, 2026), up 29% from the same quarter a year earlier. That came with a gross margin of 86% and net loss of $31M. For the full year FY2025, revenue was $292M (+44% year on year) and net income $554K. Its largest product in Q2 2026 was Recorlev at $57M, 62% of the disclosed total, well ahead of Gvoke at 24%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Sep 9, 2026John Shannon Becoming the Next Great Biopharmaceutical Company Chairman & Chief Executive Officer.Regulation FD disclosure · press release
- Aug 6, 2026Total revenue increased to over $92 million.Earnings release · press release
- Jun 30, 2026Appointment of Director Nerissa Kreher On June 29, 2026, the Board of Directors (the “Board”) of Xeris Biopharma Holdings, Inc. (the “Company”) increased the size of the Board from seven (7) to eight (8) members, thereby creating a vacancy on the Board, and appointed Nerissa Kreher, M.D., to fill such vacancy …Director or officer change · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Jun 2026 · $92.1MThe company’s own SEC segment disclosure.
- Recorlev$56.8M62%
- Gvoke$22.5M24%
- Keveyis$11.7M13%
- Royalty Contract And Other$1.1M1%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Drug Manufacturers, Specialty & Generic
Ranks #25 of 41 by RyuScore